Loading patent…
OwnerJohn BLANKENSHIP, Elaine Todd SEWELLinventors
Estimating the term…
The present disclosure relates to combination treatments with anti-androgen therapeutics, including enzalutamide, and prostate-specific membrane antigen (PSMA)-binding polypeptides including multi-specific polypeptide therapeutics that specifically target cells expressing PSMA and are capable of redirecting T-cell cytotoxicity. Such therapeutics are useful for the treatment of prostate cancer (e.g., castration-resistant prostate cancer). In one embodiment, multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides compositions comprising the multi-specific polypeptide therapeutics and one or more anti-androgen therapeutics.
A method of treating a patient with a cancer, comprising administering to the patient a prostate-specific membrane antigen (PSMA)-binding polypeptide and at least one anti-androgen therapeutic.
A method for inducing at least one of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against a cell expressing prostate-specific membrane antigen (PSMA), the method comprising:
A method for inducing redirected T-cell cytotoxicity (RTCC) against a cell expressing prostate-specific membrane antigen (PSMA), the method comprising contacting said PSMA-expressing cell with a PSMA-binding polypeptide and with at least one anti-androgen therapeutic, wherein said PSMA-binding polypeptide comprises a T-cell binding domain and wherein contacting is under conditions whereby RTCC against the PSMA-expressing cell is induced.
A prostate-specific membrane antigen (PSMA)-binding polypeptide for the manufacture of a medicament for treatment of a cancer, wherein said PSMA-binding polypeptide is administered in combination with at least one anti-androgen therapeutic.
A prostate-specific membrane antigen (PSMA)-binding polypeptide for use in treating a cancer, wherein said PSMA-binding polypeptide is to be used in combination with at least one anti-androgen therapeutic.
A composition comprising a prostate-specific membrane antigen (PSMA)-binding polypeptide and at least one anti-androgen therapeutic.
A pharmaceutical composition, comprising:
Dependencies are inferred from the claim text.